These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 21495881

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Isopropanol poisoning.
    Slaughter RJ, Mason RW, Beasley DM, Vale JA, Schep LJ.
    Clin Toxicol (Phila); 2014 Jun; 52(5):470-8. PubMed ID: 24815348
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS.
    Vorce SP, Holler JM, Levine B, Past MR.
    J Anal Toxicol; 2008 Jun; 32(6):444-50. PubMed ID: 18652752
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. "They're legal so they're safe, right?" What did the legal status of BZP-party pills mean to young people in New Zealand?
    Sheridan J, Butler R.
    Int J Drug Policy; 2010 Jan; 21(1):77-81. PubMed ID: 19321329
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication.
    Lee H, Kydd RR, Lim VK, Kirk IJ, Russell BR.
    Psychopharmacology (Berl); 2011 Feb; 213(4):707-14. PubMed ID: 20924753
    [Abstract] [Full Text] [Related]

  • 51. Analytical toxicology of emerging drugs of abuse--an update.
    Meyer MR, Peters FT.
    Ther Drug Monit; 2012 Dec; 34(6):615-21. PubMed ID: 23131695
    [Abstract] [Full Text] [Related]

  • 52. Metabolism of designer drugs of abuse.
    Staack RF, Maurer HH.
    Curr Drug Metab; 2005 Jun; 6(3):259-74. PubMed ID: 15975043
    [Abstract] [Full Text] [Related]

  • 53. Nephrotoxicity of recreational party drugs.
    Berney-Meyer L, Putt T, Schollum J, Walker R.
    Nephrology (Carlton); 2012 Feb; 17(2):99-103. PubMed ID: 22066519
    [Abstract] [Full Text] [Related]

  • 54. New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine.
    Staack RF, Fritschi G, Maurer HH.
    J Mass Spectrom; 2003 Sep; 38(9):971-81. PubMed ID: 14505325
    [Abstract] [Full Text] [Related]

  • 55. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market.
    de Boer D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, dos Reys LJ, Maes RA.
    Forensic Sci Int; 2001 Sep 15; 121(1-2):47-56. PubMed ID: 11516887
    [Abstract] [Full Text] [Related]

  • 56. Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs.
    Wada M, Yamahara K, Ikeda R, Kikura-Hanajiri R, Kuroda N, Nakashima K.
    Biomed Chromatogr; 2012 Jan 15; 26(1):21-5. PubMed ID: 21387353
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector.
    Bishop SC, McCord BR, Gratz SR, Loeliger JR, Witkowski MR.
    J Forensic Sci; 2005 Mar 15; 50(2):326-35. PubMed ID: 15813543
    [Abstract] [Full Text] [Related]

  • 59. The impact of the prohibition of benzylpiperazine (BZP) 'legal highs' on the prevalence of BZP, new legal highs and other drug use in New Zealand.
    Wilkins C, Sweetsur P.
    Drug Alcohol Depend; 2013 Jan 01; 127(1-3):72-80. PubMed ID: 22819869
    [Abstract] [Full Text] [Related]

  • 60. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
    Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH.
    J Mass Spectrom; 2003 Jun 01; 38(6):659-76. PubMed ID: 12827635
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.